Rhumbline Advisers Supernus Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 171,644 shares of SUPN stock, worth $6.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
171,644
Previous 180,274 4.79%
Holding current value
$6.15 Million
Previous $4.82 Million 10.97%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$25.77 - $35.16 $222,395 - $303,430
-8,630 Reduced 4.79%
171,644 $5.35 Million
Q2 2024

Aug 01, 2024
BUY
$25.99 - $33.85 $151,079 - $196,770
5,813 Added 3.33%
180,274 $4.82 Million
Q1 2024

May 09, 2024
SELL
$27.11 - $35.17 $88,378 - $114,654
-3,260 Reduced 1.83%
174,461 $5.95 Million
Q4 2023

Feb 08, 2024
BUY
$22.72 - $29.68 $253,941 - $331,733
11,177 Added 6.71%
177,721 $5.14 Million
Q3 2023

Nov 09, 2023
BUY
$27.57 - $32.91 $54,202 - $64,701
1,966 Added 1.19%
166,544 $4.59 Million
Q2 2023

Aug 08, 2023
SELL
$29.91 - $38.73 $280,795 - $363,597
-9,388 Reduced 5.4%
164,578 $4.95 Million
Q1 2023

May 11, 2023
BUY
$34.93 - $42.03 $314,893 - $378,900
9,015 Added 5.47%
173,966 $6.3 Million
Q4 2022

Feb 14, 2023
BUY
$31.09 - $37.88 $113,385 - $138,148
3,647 Added 2.26%
164,951 $5.88 Million
Q3 2022

Nov 10, 2022
BUY
$28.79 - $35.41 $202,739 - $249,357
7,042 Added 4.56%
161,304 $5.46 Million
Q2 2022

Aug 11, 2022
BUY
$25.33 - $34.25 $150,257 - $203,171
5,932 Added 4.0%
154,262 $4.46 Million
Q1 2022

May 12, 2022
BUY
$28.51 - $32.9 $99,129 - $114,393
3,477 Added 2.4%
148,330 $4.79 Million
Q4 2021

Feb 10, 2022
SELL
$26.37 - $34.22 $55,508 - $72,033
-2,105 Reduced 1.43%
144,853 $4.22 Million
Q3 2021

Nov 12, 2021
SELL
$23.54 - $31.39 $429,510 - $572,741
-18,246 Reduced 11.04%
146,958 $3.92 Million
Q2 2021

Aug 05, 2021
SELL
$26.72 - $33.19 $40,587 - $50,415
-1,519 Reduced 0.91%
165,204 $5.09 Million
Q1 2021

May 06, 2021
BUY
$24.15 - $31.45 $109,182 - $142,185
4,521 Added 2.79%
166,723 $4.37 Million
Q4 2020

Feb 10, 2021
BUY
$17.7 - $25.81 $161,140 - $234,974
9,104 Added 5.95%
162,202 $4.08 Million
Q3 2020

Nov 12, 2020
SELL
$20.2 - $25.05 $391,314 - $485,268
-19,372 Reduced 11.23%
153,098 $3.19 Million
Q2 2020

Aug 13, 2020
BUY
$17.09 - $24.89 $77,486 - $112,851
4,534 Added 2.7%
172,470 $4.1 Million
Q1 2020

May 06, 2020
BUY
$14.45 - $24.69 $41,876 - $71,551
2,898 Added 1.76%
167,936 $3.02 Million
Q4 2019

Feb 05, 2020
BUY
$19.93 - $29.13 $213,569 - $312,157
10,716 Added 6.94%
165,038 $3.92 Million
Q3 2019

Oct 23, 2019
BUY
$25.47 - $33.37 $83,541 - $109,453
3,280 Added 2.17%
154,322 $4.24 Million
Q2 2019

Aug 14, 2019
BUY
$29.96 - $38.87 $182,126 - $236,290
6,079 Added 4.19%
151,042 $5 Million
Q1 2019

May 01, 2019
BUY
$32.77 - $41.99 $20,186 - $25,865
616 Added 0.43%
144,963 $5.08 Million
Q4 2018

Jan 31, 2019
BUY
$30.84 - $49.51 $775,718 - $1.25 Million
25,153 Added 21.1%
144,347 $4.8 Million
Q3 2018

Nov 07, 2018
SELL
$42.7 - $56.55 $105,554 - $139,791
-2,472 Reduced 2.03%
119,194 $6 Million
Q2 2018

Aug 06, 2018
BUY
$44.1 - $59.85 $187,336 - $254,242
4,248 Added 3.62%
121,666 $7.28 Million
Q1 2018

May 02, 2018
BUY
$37.15 - $46.9 $149,751 - $189,053
4,031 Added 3.56%
117,418 $5.38 Million
Q4 2017

Feb 09, 2018
BUY
$36.4 - $42.6 $605,332 - $708,438
16,630 Added 17.19%
113,387 $4.52 Million
Q3 2017

Nov 06, 2017
BUY
$36.75 - $49.65 $3.56 Million - $4.8 Million
96,757
96,757 $3.87 Million

Others Institutions Holding SUPN

# of Institutions
282
Shares Held
60.9M
Call Options Held
27.7K
Put Options Held
11.3K
View Full List

About SUPERNUS PHARMACEUTICALS, INC.

SUPN Quotes by TradingView
  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.92B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email